Dianthus Therapeutics (DNTH) Consolidated Net Income (2017 - 2025)

Dianthus Therapeutics has reported Consolidated Net Income for 9 years, with the latest figure at -$36.6 million in Q3 2025.

• For the quarter ending Q3 2025, Consolidated Net Income fell 31.78% year-over-year to -$36.6 million; the trailing twelve-month figure through Dec 2025 stood at -$97.5 million (down 11.12% YoY), and the FY2024 full-year result was -$84.5 million, down 94.65% from the prior year.
• Consolidated Net Income for Q3 2025 stood at -$36.6 million, down from -$31.5 million in the prior quarter.
• The five-year high for Consolidated Net Income was -$7.1 million in Q1 2023, with the low at -$36.6 million in Q3 2025.
• Average Consolidated Net Income over 5 years is -$18.8 million, with a median of -$17.4 million recorded in 2021.
• Year-over-year, Consolidated Net Income soared 69.16% in 2023 and tumbled 165.66% in 2024.
• Tracing DNTH's Consolidated Net Income over 5 years: stood at -$19.3 million in 2021, then surged by 47.89% to -$10.1 million in 2022, then retreated by 4.57% to -$10.5 million in 2023, then plunged by 165.66% to -$27.9 million in 2024, then plunged by 31.17% to -$36.6 million in 2025.
• The last three Consolidated Net Income figures came in at -$36.6 million (Q3 2025), -$31.5 million (Q2 2025), and -$29.4 million (Q1 2025), per Business Quant data.

Peer Comparison